News

Video

Positive Top-Line Phase 3 Data on Novel ADHD Treatment, CTx-1301

New positive data for novel ADHD treatment.

CONFERENCE REPORTER

Ann Childress, MD, the lead investigator in the phase 3 CTx-1301-022 study, discusses the positive data, recently shared at 2023 Psych Congress. Data show that the novel treatment can last up to 16 hours, helpful for patients with long days.

Dr Childress is president of the Center for Psychiatry and Behavior Medicine, Inc, and adjunct associate professor at the University of Nevada Las Vegas School of Medicine and Touro University Nevada College of Osteopathic Medicine.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Videos
sofiko14/Adobe Stock
Miquel/Adobe Stock
NAIMAH/Adobe Stock
crizzystudio/Adobe Stock
sebra/Adobe Stock
freshidea/Adobe Stock
schizophrenia
© 2025 MJH Life Sciences

All rights reserved.